New drug tested to help control blood cancer during risky transplant
NCT ID NCT07104799
Summary
This early-stage study aims to find the safest and most tolerable dose of an investigational drug called momelotinib for people with myelofibrosis, a serious bone marrow cancer. It will involve up to 28 patients who are already scheduled to receive a stem cell transplant, a standard but intensive treatment. The main goal is to see if giving momelotinib during and for about a year after the transplant is safe and helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.